Cite Score:
0.89
CITE SCORE SCOPUS

Can Biomarkers Improve Ability of NPI in Risk Prediction? A Decision Tree Model Analysis

AUTHORS

Mohammad Reza Baneshi 1 , * , P Warner 2 , N Anderson 2 , S Tovey 3 , J Edwards 3 , JMS Bartlett 4

1 Health School, Kerman Medical University, Department of Biostatistics and Epidemiology, Kerman, Iran; Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom

2 Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom

3 Section of Surgical and Translational Sciences, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom

4 Endocrine Cancer Group, University of Edinburgh, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, United Kingdom

How to Cite: Baneshi M R , Warner P, Anderson N, Tovey S, Edwards J, et al. Can Biomarkers Improve Ability of NPI in Risk Prediction? A Decision Tree Model Analysis, Int J Cancer Manag. 2010 ; 3(2):e80664.

ARTICLE INFORMATION

International Journal of Cancer Management: 3 (2); e80664
Published Online: June 30, 2010
Article Type: Research Article
Received: October 23, 2009
Accepted: November 19, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: The Nottingham Prognostic Index (NPI) is widely-used in the UK for risk stratification of breast cancer patients. This paper aims to evaluate the ability of this index to detect patients with sufficiently low risk of recurrence that they could be spared harsh treatments, and to construct an enhanced prognostic rule that integrates biomarkers with clinical variables to achieve better risk stratification.

 Methods: We undertook review of published studies of outcomes in risk groups derived by applying NPI, and report estimated event-free rates extracted from Then we analysed biological and clinical variables for 401 ER+ patients, to develop a Tree-based Survival Model (TSM), for risk prediction, and estimated event-free rates by resulting risk-groups, Kaplan-Meier (K-M) curves corresponding to TSM and NPI were plotted.

Results: We concluded that NPI does not distinguish low risk patients with a sufficiently high event-free rate to make it likely clinicians would decide treatments with potential harmful side effects can be avoided in that group. On the other hand, in the decision tree constructed, utilising 3 biomarkers, nodal status and tumour size, the 4 risk groups were clearly diverged in terms of event-free rates.

Conclusion: There is considerable potential for improved prognostic modelling by incorporation of biological variables into risk prediction. Whilst low risk patients identified by our TSM model could potentially avoid systemic treatment, higher risk patients might require additional treatment, including chemotherapy or other adjuvant treatment options. However, the decision tree model needs to be validated in a larger clinical trial cohort.

Keywords

Breast neoplasm Tissue microarray data NPI Tree-based survival methods Missing data

© 2010, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

Full text is available in PDF.
 

COMMENTS

LEAVE A COMMENT HERE: